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ABSTRACT The human epidermal growth factor receptor (HER/ErbB) system comprises the epidermal growth factor receptor
(EGFR/HER1) and three other homologs, namely HERs 2–4. This receptor system plays a critical role in cell proliferation and
differentiation and receptor overexpression has been associated with poor prognosis in cancers of the epithelium. Here, we
examine the effect of coexpressing varying levels of HERs 1–3 on the receptor dimerization patterns using a detailed kineticmodel
for HER/ErbB dimerization and trafﬁcking. Our results indicate that coexpression of EGFRwith HER2 or HER3 biases signaling to
the cell surface and retards signal downregulation. In addition, simultaneous coexpression of HERs 1–3 leads to an abundance of
HER2-HER3 heterodimers, which are known to be potent inducers of cell growth and transformation. Our new approach to use
parameter dependence analysis in experimental design reveals that measurements of HER3 phosphorylation and HER2
internalization ratiomayprove to be especially useful for the estimation of criticalmodel parameters. Further, we examine the effect
of receptor dimerization patterns on biological response using a simple phenomenological model. Results indicate that
coexpression of EGFR with HER2 and HER3 at low to moderate levels may enable cells to match the response of a high HER2
expresser.
INTRODUCTION
The HER system of receptor tyrosine kinases plays an
important role in growth, proliferation, and differentiation
of epithelial cells. This receptor system consists of four
members—HER1, which is also known as the epidermal
growth factor receptor (EGFR); and HERs 2–4. These
receptors are also known as ErbBs 1–4 (1). In addition to
the important physiological role of the HER system, these
receptors play a key role in transformation and tumor pro-
gression. For instance, overexpression of HER2 is associated
with poor prognosis in breast cancers with 25–30% of tumors
from this tissue displaying signiﬁcant HER2 overexpression
(2). Although the link between HER overexpression and
tumorigenesis is well documented, a number of details re-
garding the molecular mechanisms that are involved in this
process remain to be elucidated.
The importance of the HER system in physiology and
pathology coupled with the scientiﬁc desire to understand the
general principles underlying growth factor signaling have
led to extensive research in this area (3–9). It is known that
all members of this receptor family display signiﬁcant ho-
mology, with each of these receptors having distinct prop-
erties such as ligand binding or receptor trafﬁcking (6,10).
For example, the EGFR is rapidly internalized and degraded
upon binding its ligand EGF (11,12), whereas the other
receptors in the family do not display signiﬁcant ligand-
induced internalization and/or recycle rapidly back to the cell
surface after endocytosis (10,13–15). Further, ligand binding
induces dimerization of HER family receptors where various
combinations of homo- and heterodimeric species can be
formed (16–18). Dimerized receptors undergo trans-phos-
phorylation, which activates downstream signaling path-
ways such as the MAPK, PI3K/Protein Kinase B, and PKC
pathways via the binding of signaling adaptors to phospho-
tyrosine sites on the receptor cytoplasmic tails (19). There is
considerable evidence suggesting that the types of receptor
heterodimers that are formed and their trafﬁcking properties
are important determinants of the cellular response to HER
family ligands (17,20–22).
The important role of dimer identity in driving the cellular
response is exempliﬁed by the HER2-HER3 heterodimer,
which has been reported as being a potent mitogenic and
oncogenic unit (22–26). This is despite the fact that HER3
has impaired tyrosine kinase activity (27) and HER2 is
devoid of an activating ligand (28). The potency of this
dimer is thought to stem from the trafﬁcking properties of
this dimer, which tend to prolong signaling (13,15), and from
the unique ability of HER3 to efﬁciently engage the pro-
survival PI3K/PKB pathway (29,30).
In general, it is clear that the molecular mechanisms,
underlying the manner in which heterodimer identity con-
trols the cellular response, are complex. It has been reported
that the speciﬁc tyrosine sites on the cytoplasmic tail of a
receptor that end up getting trans-phosphorylated depend
upon the speciﬁc HER member with which the receptor
dimerizes (31). This would in turn cause qualitative changes
in the signaling properties of the very same HER receptor
depending upon its dimerization partner, and each dimer
type may be capable of engaging a unique complement of
cell-signaling pathways. In addition, since the heterodimers
possess distinct trafﬁcking properties, the spatial location
(plasma membrane versus internal compartments) and the
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duration of the phosphorylation signal would also depend
upon dimer identity. Therefore, knowledge of the types of
heterodimers formed in cells expressing various levels of
HER molecules may pave the way toward unraveling the
connections between receptor expression levels and cell
phenotype. We use the term ‘‘cell phenotype’’ to character-
ize such eventual biological responses of the cell as cell
migration, proliferation, and transformation.
Here, we describe the development of a multitiered pre-
dictive model that strives to establish a link between receptor
expression levels and cell phenotype for the HER system.
The current state of quantitative information available on the
HER system provides us with an ability to predict receptor
heterodimerization and trafﬁcking in an accurate fashion
using detailed kinetic modeling. We construct such a kinetic
model to generate predictions about the receptor dimeriza-
tion patterns in cells expressing varying levels of the re-
ceptors EGFR, HER2, and HER3. In addition, we use the
model as a guide to identify the types of experiments nec-
essary to accurately parameterize it for any given cell type.
These are important and necessary steps in the context of
model development and reﬁnement. Fig. 1 A shows our
conceptual framework for developing and reﬁning predictive
mathematical models. Given a set of system inputs X, a
model is expected to generate predictions about a set of
variables Y, which are functionally relevant and may be
difﬁcult to measure. In our case, X denotes ligand dosages
and receptor expression levels and Y denotes the number and
location of activated dimers of various types within the cell.
This article describes the setting-up and parameterization of
a model for EGFR family of receptors using values obtained
from literature. Furthermore, we describe how the transition
to the parameter estimation and validation phase can be
accomplished through the systematic design of experiments
using the model predictions.
The kinetic model with multiple receptor types still leaves
us short of our stated goal of creating a prediction engine for
cell phenotype. The development of a kinetic model linking
receptor expression levels to biological outcome is restricted
by the paucity of detailed mechanistic information on how
the receptor dimerization pattern Y affects the biological
outcome. This necessitates a multitiered approach to the
problem depicted in Fig. 1 B. Here we advocate the use of a
phenomenological equation to establish the link between the
dimerization pattern Y for the HER family and the biological
outcome Z. We consider a simple linear representation for
the above and present results on how the phenotype would
vary based on the parameter values of this phenomenological
equation. The phenomenological equation used here can be
subsequently reﬁned as more data about biological outcomes
under different environmental cues becomes available. We
note that Hendriks et al. (32) have recently employed a
similar approach to dissect the relative contributions of
EGFR and HER2 to ERK signaling in human mammary
epithelial cells.
Using our kinetic model, we demonstrate how the current
literature on rate constants for receptor-ligand binding and
dimerization lead naturally to the enhanced formation of
HER2-HER3 heterodimers when HERs 1–3 are coex-
pressed. When combined with the potency of the HER2-
HER3 dimer, this dimerization pattern results in a marked
effect on the cell phenotype. Thus, coexpression of all three
receptors at low to moderate levels may enable a cell to
match the phenotype of a cell expressing EGFR and very
high levels of HER2. In addition to presenting simulation
results using the kinetic model, we employ the model to
design experiments aimed at parameter estimation. These
exercises reveal that measurements of HER3 phosphoryla-
tion in cells coexpressing EGFR and HER3 and the HER2
internalization ratio in cells coexpressing EGFR and HER2
may be especially useful for the estimation of critical model
parameters. The model we present here can serve as a plat-
form to design experiments and to gain a deeper insight into
the manner in which the HER system functions.
FIGURE 1 Steps of kinetic model development for ErbB family of
receptors. (A) Schematic representation of the model development process.
The central item is a detailed kinetic model of associations among HER
receptors that is intended to convert inputs on receptor expression levels and
ligand dosages X to receptor dimerization pattern Y. Setting up of the kinetic
model is described in detail in text. In addition, the model is used to design
experiments for parameter estimation to facilitate the transition to the next
phase of model reﬁnement. (B) Schematic of two-tiered modeling approach
to relate HER expression levels to cell phenotype. The model for the HER
receptor family is used to predict the receptor dimerization patterns in the
cell. A phenomenological equation is then used to link model predictions to
the cell phenotype estimation.
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METHODS
Kinetic model for HER dimerization
For given expression levels of HERs and stimulating ligand dosages, our
integrated model of receptor dimerization and trafﬁcking is capable of
predicting the time-dependent receptor dimerization patterns. Fig. 2 presents
the various components of our mathematical model. The model was for-
mulated and solved as a system of ordinary differential equations. Despite
the relatively low receptor copy numbers encountered in our model it was
found that a deterministic treatment yielded results that were in good
agreement with those obtained using dynamic Monte Carlo simulations (33)
of the corresponding stochastic problem (results not shown). Further,
knowledge of the magnitude of stochastic ﬂuctuations in species concen-
trations is not critical to our current study. Hence, we have opted to use the
computationally less demanding deterministic approach. The governing
equations and the solution methodology for the kinetic model are described
below. Machine-readable versions of the model and the simulation code can
be obtained from the authors upon request.
Reactants
We constructed our kinetic model of HER receptor activation with the
objective of predicting the abundance and types of activated receptor dimers
formed when cells expressing various levels of EGFR, HER2, and HER3
are subjected to ligand stimulation. In the model, each individual receptor
is assumed to be in one of four possible states: 1), ligand free and un-
phosphorylated (FU); 2), ligand bound and unphosphorylated (BU); 3),
ligand free and phosphorylated (FP); and 4), ligand bound and phosphor-
ylated (BP). Since HER2 does not bind any ligands, it is restricted to two
possible states (FU and FP). Receptors can either exist as monomers or be
part of dimers. To illustrate the naming convention, R1BP is a ligand-bound
and phosphorylated EGFR monomer, while R1BPR2FP is an EGFR-HER2
heterodimer where EGFR is bound by its ligand and both receptors are
phosphorylated. Having four possible states, EGFR and HER3 can form
10 distinct types of homodimers, while HER2 can form three types of
homodimers. In all, the model contains 55 distinct dimer species: 10 (EGFR)
1 3 (HER2)1 10 (HER3)¼ 23 types of homodimers; and 8 (EGFR-HER2)
1 16 (EGFR-HER3) 1 8 (HER2-HER3) ¼ 32 types of heterodimers.
Adding the 10 receptor monomers and the two ligand species (epidermal
growth factor, EGF, i.e., the EGFR ligand; and neuregulin, NRG, i.e., the
HER3 ligand) results in 67 total reactants. Each of these reactants can exist
in one of four possible cell compartments (plasma membrane, smooth-pit
endosomes, coated-pit endosomes, and sorting-late endosomes).
Reactions
The concentration of a species in a speciﬁc compartment can change for two
reasons. The species can be 1), generated and destroyed through a bio-
chemical reaction; or 2), can be transported in and out of the compartment
due to vesicle trafﬁcking. The following sections present a brief description
of the biochemical and trafﬁcking reactions in the model. The detailed
mathematical equations governing the model are provided in Appendix A.
Biochemical reactions. The model includes three types of biochemical
reactions: 1), receptor-ligand binding; 2), receptor dimerization; and 3),
receptor phosphorylation. The process of obtaining a dually phosphorylated
receptor dimer is allowed to occur in any order. For instance, a receptor
monomer can spontaneously undergo phosphorylation, albeit at a low rate,
after which a dimerization reaction can occur, yielding an active dimer.
However, the rate constants are such that the kinetically dominant pathway
for active dimer formation is one in which receptor-ligand binding leads to
dimerization, followed by receptor trans-phosphorylation. The combinatorial
FIGURE 2 Reactant species and reactions
in the mathematical model. (A) Reactants in
the mathematical model. The ligands and the
possible states of the receptors in our kinetic
model are shown. The nomenclature used for
each of the reactant species is indicated at
the bottom of each cartoon. EGFR and HER3
can exist in one of four states. Since HER2
does not bind any ligands, it has only two
possible states. Receptors can either be found
in monomeric form as depicted, or can be part
of dimers. As an illustration, R1FUR3BP is
one such dimer species formed between an
EGFR and a HER3 molecule. (B) Bio-
chemical reaction classes in the model. The
reactions of (1) receptor-ligand binding, (2)
receptor dimerization, and (3) phosphoryla-
tion are depicted in canonical form. (C)
Schematic of the trafﬁcking portion of the
model. The compartments involved in recep-
tor trafﬁcking are indicated. The biochemical
reactions shown in panel B are overlapped
with the receptor trafﬁcking model depicted
in panel C to arrive at the spatial distribution
of the various receptor species within the cell.
Panel C is adapted from Resat et al. (42).
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nature of the dimerization problem and the fact that we allow for explicit
representation of the ligand binding and phosphorylation states of the re-
ceptors in a dimer results in a large number of reactant species and reactions
in the model. The model contains 308 distinct biochemical reactions for
which rate constants need to be assigned. These rate constants in our model
are described in terms of a basal rate and an enhancement factor based on
phosphorylation state and ligand occupancy (Table 1). The exact manner in
which the parameters listed in Table 1 are used to compute the individual
rate constants is described in Appendix B. We note that other researchers
have used similar notions of reaction classes and rules to parameterize large
models of signal transduction (34–38). In these models, as well as in our
work, receptors are allowed to have multiple states, each of which is in-
cluded as a distinct reactant species in the model. This leads to a large
number of reactions that need to be parameterized. The problem is alleviated
by assigning rate constants for entire classes of reactions and formulating
rules for how the rate constants would change based on speciﬁc receptor
modiﬁcations. We follow this well-documented approach in our current
work.
Some of the key assumptions regarding the biochemical rate constants in
the model are as follows:
1. With respect to ligand binding, on- and off-rates for binding are
assumed to depend upon the identity of the dimer. The dissociation of
neuregulin from HER2-HER3 heterodimers is assumed to be 10-times
slower than that from other species involving HER3 (18,39). Further, in
EGFR-HER3 heterodimers, the presence of NRG halves the EGF on-
rate and increases the EGF off-rate by a factor of 1.5 (40).
2. Receptor dimerization is assumed to be a diffusion-limited process and
thus occurs at a constant rate independent of the species participating
in the dimerization reaction. Dimer dissociation is assumed to depend
upon the species identity and accounts for the greater stability of certain
HER dimers compared to others seen in practice (18). We assume a low
basal rate for the dissociation of a dimer where both partners are ligand-
bound and phosphorylated. Removal of the ligand or the phosphate
group is assumed to decrease the dimer stability and hence facilitates
dissociation. This is in agreement with the currently held views of HER
receptor dimerization wherein ligand binding is thought to stabilize the
dimer by inducing a conformational change (7,41).
3. Receptor phosphorylation is assumed to occur at a low basal rate when
both receptors are unoccupied by ligand and are unphosphorylated.
Ligand binding and the presence of a phosphate group on one of the
receptors is assumed to increase the phosphorylation rate. This assump-
tion envisions a molecular model wherein ligand-binding results in a
conformational change, which brings the receptor kinase domains in
direct opposition to each other, thereby facilitating trans-phosphoryl-
ation. In cells, HER receptors are dephosphorylated by phosphatases.
Here we assume that dephosphorylation occurs at a low basal rate in
dimers which are dually phosphorylated and have both receptors
engaged by ligand. Such dimers are expected to have the highest level
of conformational stability, thus preventing access to the phosphatase.
In addition, we assume that the removal of a phosphate group from one
of the receptors and the removal of each ligand molecule enhances the
dephosphorylation rate.
Trafﬁcking. The trafﬁcking portion of the model is based on our earlier work
on EGFR signaling (42). The parameters for the trafﬁcking portion of our
model and the details of how these parameters are employed in the model are
described in Table 1 and in Appendix B, respectively. Brieﬂy, receptors in
the plasma membrane (PM) are internalized either through a constitutive
pathway involving smooth-pit endosomes or a ligand-induced pathway
involving coated-pit endosomes. The incorporation rates of receptor species
into coated-pit vesicles depend upon the ligand-binding state of the receptors
as deﬁned by the receptor incorporation factors in Table 1. Smooth- and
coated-pit endosomes that constitute early endosomic (EE) vesicles are
either allowed to recycle back to the plasma membrane or merge into the late
endosomes (LE). When an EE vesicle merges with either the plasma
membrane or the LE, all of its contents are assumed to be transferred to the
target compartment. The rates at which EE vesicles are formed, recycled to
the PM, and targeted to the LE are assumed to depend upon whether the
vesicle is a smooth-pit or a coated-pit compartment. Receptors go through a
second stage of sorting in the LE wherein vesicles are formed from the LE
and can either be targeted to the lysosome or recycled back to the PM. A
vesicle from the LE that fuses with the lysosome ends up having its contents
degraded. The enhanced propensity of ligand-bound EGFR to get targeted to
lysosomes for degradation is captured by the degradation multipliers in
Table 1. The mathematical equations governing the formation and sorting of
vesicles and how this affects species concentrations are described in detail in
Appendix A.
Parametric sensitivity analysis of the
kinetic model
Parametric sensitivity of the receptor dimerization pattern
The results generated by a kinetic model are a function of the rate constants
used to deﬁne the mathematical model. In our current model, we have a set
of 321 rate constants for the individual biochemical and trafﬁcking reactions.
Although this is an apparently large parameter set, all the rates are essentially
derived from a reduced set of 54 distinct parameters that completely deﬁne
the model. To facilitate the characterization of the model, it is instructive to
examine the effect of varying each of these parameters on the model outputs.
The functionally relevant model outputs in this case are the number of
phosphorylated dimer species of each type present both in the cell as a whole
and at the cell surface. We performed a sensitivity analysis by allowing a
10% increase in each of the parameters one at a time and examining the
impact of the parameter variation on the system outputs. Control parameters
were identiﬁed as those that induced a large change in the number of
activated receptor dimers. We note that more robust approaches to sensi-
tivity analysis do exist that enable the determination of the effect of pa-
rameter changes on the model over larger regions of the parameter space
(43,44). We plan on addressing rigorous sensitivity analysis and parameter
estimation issues in future work using real experimental data for model
reﬁnement.
Deﬁning the dependence of experimental observables on
model parameters
The rate constants in our model have been largely derived from experi-
mental observations in model systems and are known to various degrees of
conﬁdence. For the model to be used for a speciﬁc experimental system, it is
important to determine the applicability of these values to the system in
question. This can be done by designing a set of experiments, which can then
be used in conjunction with the model for estimation of the model pa-
rameters. Parameter estimation involves the ﬁtting of a predeﬁned model
to experimental measurements using techniques such as nonlinear least-
squares regression. Nonlinear regression is a nontrivial problem if the
number of parameters to be estimated is large. The process of parameter
estimation could be simpliﬁed if the model were used as a guide to design
the experiments to be performed. To this end, we attempted to deﬁne a
systematic methodology to decide which experimental output would yield
the best data set for estimating speciﬁc model parameters. These measurable
quantities can then be chosen as the most relevant observable targets in
experimental studies. For our speciﬁc case, we considered cell lines
expressing various combinations of EGFR, HER2, and HER3 and sought to
determine both the cell line and the speciﬁc measurement in each cell line
that would have the highest information content for parameter estimation.
The experimental observables included in this analysis were the total
receptor mass of EGFR, HER2, and HER3, the fractional phosphorylation of
the three receptors, and the Inside/Surface ratio (In/Sur) of the phosphor-
ylated forms of the three receptors. These outputs are routinely measured
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by us and by others in cell lines expressing HER molecules using stan-
dard biochemical techniques such as ELISAs and/or Western blots (42,
45,46).
The kinetic model was run and the values of experimental observables
were generated as a function of time using the base parameter set listed in
Table 1 (base curve) and a parameter set with a 10% increase in a single
model parameter (modiﬁed curve). The difference between the base curve
and the modiﬁed curve was quantiﬁed using the relative root-mean-squared
difference (RMSD) between the two curves, which is computed using the
fractional change between the two curves at speciﬁc sampling time points.
We chose a uniform sampling scheme with seven time points between 0 s
and 2 h of ligand stimulation. The relative RMSD between the two curves
was then computed as
Relative RMSD ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
+
N
i¼1
f(MPi  Bi)=Big2
N
vuuut
; (1)
where Bi is the model output generated at the i
th time point using the base
parameter values listed in Table 1, Mi
P is the model output generated at
the ith time point generated using a parameter set with a 10% increase in
parameter P, and N is the total number of time points. This relative RMSD is
an indicator of how sensitive an experimental output is to the parameter P,
which is altered to generate the modiﬁed curve. Here, we computed the
relative RMSD for the various model parameters using the experimental
observables as outputs for each of four cell lines:
1. A cell line expressing 200,000 copies of EGFR alone.
2. A cell line coexpressing 200,000 molecules each of EGFR and HER2.
3. A cell line coexpressing 200,000 molecules each of EGFR and HER3.
4. A cell line expressing 200,000 receptors each of EGFR, HER2, and
HER3.
These RMSD values were then used to judge the best possible experiment to
perform for estimating a given model parameter.
TABLE 1 Parameters used in the model
Parameter
No. Parameter description Value
Receptor-ligand binding rates
1 BR for EGF binding. 2.38 3 106/nM/s
2 BR for NRG binding. 2.38 3 106/nM/s
3 Multiplier for EGF binding
rate in endosomes.
0.135
4 Multiplier for NRG binding rate
in endosomes.
0.135
5 Multiplier for EGF binding to
EGFR-HER3.
0.5
Ligand dissociation rates
6 BR for EGF dissociation. 4 3 103/s
7 BR for NRG dissociation. 4 3 103/s
8 Multiplier for EGF dissociation
in endosomes.
4.125
9 Multiplier for NRG dissociation
in endosomes.
8.25
10 Multiplier for NRG dissociation
from HER2-HER3.
0.1
11 Multiplier for EGF dissociation
from EGFR-HER3.
1.5
Receptor dimerization rates
12 Receptor dimerization rate. 1 3 102/nM/s
Dimer dissociation rates
13 BR for EGFR homodimers. 1 3 102/s
14 BR for HER2 homodimers. 2.5 3 101/s
15 BR for EGFR-HER2. 2 3 102/s
16 BR for HER3 homodimers. 1 3 102/s
17 BR for HER2-HER3. 2 3 102/s
18 BR for EGFR-HER3. 1 3 102/s
19 Multiplier when phosphate is removed. 2
20 Multiplier when ligand is removed. 5
Receptor phosphorylation rates
21 BR for EGFR monomer. 1 3 103/s
22 BR for HER2 monomer. 2 3 104/s
23 BR for EGFR homodimers. 1 3 102/s
24 BR for HER2 homodimers. 8 3 103/s
25 BR. for EGFR-HER2. 8 3 103/s
26 BR for HER2-HER3. 8 3 103/s
27 BR for EGFR-HER3. 8 3 103/s
28 Multiplier when a receptor is
phosphorylated.
3
29 Multiplier when a receptor is bound. 2
Receptor dephosphorylation rates
30 BR for EGFR monomer. 5 3 102/s
31 BR for HER2 monomer. 5 3 102/s
32 BR for HER3 monomer. 5 3 102/s
33 BR for EGFR homodimers. 5 3 103/s
34 BR for HER2 homodimers. 5 3 103/s
35 BR for EGFR-HER2. 5 3 103/s
36 BR for HER3 homodimers. 5 3 103/s
37 BR for HER2-HER3. 5 3 103/s
38 BR for EGFR-HER3. 5 3 103/s
39 Multiplier when phosphate is removed. 2
40 Multiplier when ligand
is removed.
4
Vesicle trafﬁcking rates
41 CP vesicle formation. 2.1 3 101/s
42 SP vesicle formation. 2.1 3 101/s
(Continued)
Table 1 (Continued)
Parameter
No. Parameter description Value
43 SP vesicle recycling. 6.9 3 104/s
44 CP vesicle recycling. 2.07 3 103/s
45 SP vesicle merging with LE. 1.61 3 103/s
46 CP vesicle merging with LE. 2.3 3 104/s
47 SP formation from LE. 2.47 3 104/s
48 Lysosome formation from LE. 1.3 3 105/s
Receptor incorporation factors
49 Factor for EE vesicles. 7.94 3 104
50 Multiplier for ligand-bound
EGFR.
15.5
51 Multiplier for ligand-bound
EGFR-HER2.
5.4
52 Multiplier for ligand-bound
EGFR-HER3.
5.4
Degradation multipliers
53 Multiplier for single-ligand-bound
EGFR.
3
54 Multiplier for doubly-bound EGFR
homodimers.
6
BR stands for the basal rate. Sources of these parameters and the manner in
which these parameters are used to obtain rate constants for speciﬁc
reactions are described in Appendix B.
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Application of the results of the kinetic model to
the prediction of cell phenotype
To relate the dimerization results to the cellular phenotype we begin with a
simple representation wherein the phenotype is a linear function of the
activated dimers in the cell. Thus, the phenotype P is expressed as
P ¼ ½pYðEGFR-EGFRÞ1 ½pYðEGFR-HER2Þ
1b½pYðEGFR-HER3Þ1 g½pYðHER2-HER3Þ; (2)
where the quantities within square brackets represent the total number of
phosphorylated dimers of the speciﬁed type. These quantities are either eval-
uated at a ﬁxed time-point 1 h after the introductionof the ligand stimulus, or are
obtained as an integral over the ﬁrst two hours after ligand stimulation. In Eq.
2, b represents the relative potency of activated EGFR-HER3 heterodimers
compared toEGFRhomodimers andEGFR-HER2heterodimers. Similarly,g
is a potency factor for HER2-HER3 heterodimers. Here, we compute the
phenotype valueP¼P* of a reference cell line expressing 200,000EGFRand
600,000 HER2 molecules. This cell line is a high HER2 expresser and is
assumed to possess the target phenotype. We then determine the relative
potenciesb andg thatwould be necessary to obtain a phenotype value ofP* in
cells expressing varying levels of HER2 and HER3. This approach implicitly
assumes that the overall biological response of the cell, i.e., cell migration,
proliferation, and transformation, can be represented with a phenomenolog-
ical expression that uses the number of activated receptors as parameters.
RESULTS AND DISCUSSION
The ordinary differential equations comprising the kinetic
model were solved using the parameter values listed in Table
1 to obtain the dimerization and receptor phosphorylation
proﬁles as a function of time for cells expressing varying
levels of EGFR, HER2, and HER3. For all the simulations, a
saturating ligand dose of 100 nM was employed for both
EGF and NRG. A receptor expression level of 200,000
receptors was employed unless stated otherwise. After the
characterization of model behavior for the base parameter
set, sensitivity of the system outputs and experimental ob-
servables to the variations in the parameters was examined.
The dependence of the receptor dimerization pattern (which
we deﬁned as the system output) upon the parameter values
enables us to identify the key control parameters in the
model. The dependence of experimental observables on the
parameters provides us with information about the types of
experiments to perform to estimate system parameters. After
the characterization of the kinetic model, the phenomeno-
logical equation (Eq. 2) was used to relate the predictions of
the kinetic model to cell phenotype. Results are presented for
the manner in which the phenotype varies as a function of
receptor expression levels for various parameter inputs to the
phenomenological equation.
Behavior of the HER family for the base
parameter set
Dimerization pattern when EGFR, HER2, and HER3
are coexpressed
The pattern of dimerization when HER family receptors are
coexpressed is important since each of the dimer species
might be capable of activating a unique complement of
downstream signaling pathways (47,48). We employed our
model to determine the dimerization patterns when HERs
1–3 are equally coexpressed (Fig. 3). For these simulations,
cells coexpressing 200,000 molecules each of EGFR, HER2,
and HER3 were subjected to saturating concentrations of
EGF and NRG and the dimerization fractions were deter-
mined. The dimerization ratio for each HER family member
is computed as the fraction of the receptor that is present as
part of a speciﬁed dimer type. It should be noted that the
actual number of receptor homodimers would be one-half the
dimerization ratio value computed for the homodimer. As an
illustration, a ratio of 0.4 for EGFR homodimers would imply
that 40% of the total cellular EGFR is present in the form of
EGFR-EGFR dimers. Thus, the number of EGFR homo-
dimer moieties expressed as a fraction of the total number of
EGFR molecules would be only 0.2.
As seen in Fig. 3, after a brief transient lasting for;2 min,
species concentrations achieve relative stability. In the case
of the EGFR (Fig. 3 A), the EGFR-HER2 heterodimer is the
most abundant species accounting for ;35% of the total
receptor population. Approximately 40% of the EGFR mol-
ecules are part of EGFR homodimers. Hence, EGFR homo-
dimers account for 20% of all EGFR-containing moieties.
The number of EGFR-HER3 heterodimers is approximately
the same as the number of EGFR homodimers. Monomers
account for ,10% of total EGFR. Overall EGFR-HER2
heterodimers are the most abundant EGFR containing
species. Using a similar analysis it is clear from Fig. 3, B
and C, that HER2-HER3 heterodimers are more abundant
than any other species bearing either HER2 or HER3. HER2-
HER3 heterodimers account for nearly 45% of the total
HER2 and HER3 receptor numbers. The increased formation
of HER2-HER3 heterodimers in comparison to the other
dimer types has also been seen in experiments (18). In our
model, the rate constants for dimerization are not strong func-
tions of the receptor type to which the monomers belong.
However, the rates are strong functions of ligand occupancy.
Thus, the increased formation of HER2-HER3 heterodimers
occurs in part due to the increased NRG afﬁnity of this dimer.
It should be noted that the abundance of a particular dimer
type is a function both of the dimerization afﬁnity and of the
relative local species concentrations. In our model, the di-
merization afﬁnities of the different species are in the same
order of magnitude (Table 1). The local species concentra-
tions are thus critical determinants of the dimerization pat-
tern seen in the cell. In this regard, our model is in agreement
with that of Hendriks et al. (45) for cells coexpressing EGFR
and HER2.
HER2 has a more pronounced effect on EGFR trafﬁcking
than HER3
An important consequence of heterodimerization is that
HER receptors are expected to exert an inﬂuence on the
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localization of their receptor partners. For instance, while
EGFR is expected to internalize and commit to the lysosomal
pathway, HER2 and HER3 have a much higher tendency to
recycle back to the plasma membrane (PM) upon ligand
binding (6). In contrast, an EGFR-HER2 heterodimer is
expected to have an intermediate trafﬁcking behavior. To
investigate the effect of heterodimerization on receptor
localization, we quantiﬁed the inside-to-surface (In/Sur) ratio
for the HER molecules in our model. As seen in Fig. 4 A, the
In/Sur ratio of EGFR increases immediately after ligand
stimulation and takes ;40 min to reach a steady-state value.
Comparison of this 40-min lag for achieving receptor local-
ization steady state with the ;2 min transient for receptor
dimerization (see Fig. 3) reveals the fact that the trafﬁcking
and biochemical reactions in the model occur on signiﬁcantly
different timescales. When a cell expresses EGFR alone,
after the initial transient the In/Sur ratio of EGFR reaches a
constant value of 9. In other words, 90% of EGFR gets
internalized, and only 10% of the receptor population can be
found on the cell surface. This reﬂects the propensity for
ligand-induced EGFR downregulation. Coexpression of
EGFR with HER3 alone results in 14% of the EGFR at the
cell surface even when EGF alone is used as the stimulating
ligand. This increased surface retention is a consequence of
the conﬂicting trafﬁcking properties of these two receptors
discussed above. When both EGF and NRG are used as
agonists, we get an EGFR surface expression of 15.6%. In
comparison to HER3, HER2 has a slightly more pronounced
effect on EGFR localization with a ratio of ;4.5, i.e., 18%
EGFR surface expression. Coexpression of equal amounts
of all three receptors results in only a marginal increase in
EGFR surface expression compared with coexpression of
EGFR and HER3 alone. Overall, both HER2 and HER3
impede the internalization of EGFR, thereby resulting in a
prolonged surface-localized EGFR phosphorylation signal.
However, it is difﬁcult to predict the importance of this
change because, although the number of surface EGFR
molecules roughly doubles between a cell line expressing
EGFR alone and that coexpressing equal amounts of
EGFR and HER2, the absolute change is only 8% and this
modest change may not be enough to alter the biological
response.
Next, we examined the effect of receptor coexpression on
EGFR degradation. It is known that EGFR degradation me-
diated by receptor ubiquitination in the internal compart-
ments is a mechanism for signal termination. Our results
(Fig. 4 B) indicate that coexpression of EGFR with HER2
and HER3 reduces the EGFR degradation rate, thereby
prolonging the signal. This is a consequence of the effect of
heterodimerization on EGFR trafﬁcking and could be an
additional mechanism by which HER2 and HER3 modulate
EGFR signaling.
To summarize, coexpression of EGFR with HER2 and
HER3 causes 1), increased EGFR surface localization;
and 2), reduced receptor degradation. With respect to cell
FIGURE 3 Receptor dimerization hierarchy. The response of cell lines
expressing 200,000 molecules each of EGFR, HER2, and HER3, exposed to
saturating concentrations of both EGF and NRG, was simulated. The ﬁgure
presents the fraction of the total receptor population of each type present as
part of the speciﬁed type of monomer/dimer. The dimer type is indicated on
top of each curve, while the receptor whose distribution is being analyzed is
noted on the Y axis. The dimerization ratios were computed based on total
receptor numbers present in the entire cell and therefore include receptors
both at the plasma membrane and in the internal compartments. Dimeriza-
tion patterns for (A) EGFR, (B) HER2, and (C) HER3 are presented.
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transformation, both of these factors may play an important
role. It is still a matter of debate as to whether receptors
continue to signal as effectively once they are inside the cell
and are part of either early or late endosomes (49). It is
conceivable that signaling is accomplished most effectively
when the receptors are at the PM for various reasons, such as
having a better chance to interact with the readily available
membrane-associated proteins involved in the receptor
signaling pathway (50). Hence increased PM localization
could enhance EGFR signaling via pathways such as the
MAPK and PLC-g pathways. The dynamics of MAPK
signaling is known to have an effect on the type of
phenotypic changes induced in cells. For instance, studies
have shown that while sustained MAPK activation induces
cell proliferation, MAPK transients induces differentiation in
mammalian PC12 cells (51). Thus, reduced degradation of
EGFR, when coexpressed with HER2 and HER3, could have
a bearing on downstream signaling transients, thereby alter-
ing the eventual cellular response.
HER2-mediated lateral information transfer between
EGFR and HER3
It is of interest to determine the mechanism by which EGFR
and HER3 interact with each other in cells coexpressing
HER1–3. One possibility is that HER2 is the lateral informa-
tion carrier between EGFR and HER3/4 receptors by virtue
of its ability to form a large number of heterodimers with
HER family receptors (18). In other words, the dominant
mechanism by which EGFR and HER3/4 modify each
other’s behavior could be through the involvement of HER2.
We examined whether our model yielded such behavior
using simulations where the EGFR expression was kept
ﬁxed at 200,000 receptors and the expression levels of HER2
and HER3 were varied (Fig. 5). Firstly, we performed sim-
ulations of cells coexpressing EGFR and HER3 alone and
examined the extent of EGFR phosphorylation (Fig. 5 A). It
should be noted that the EGFR binds EGF, and is not known
to have a signiﬁcant binding afﬁnity for NRG (39). Hence,
cells expressing EGFR and HER3 when stimulated with
neuregulin alone can undergo EGFR phosphorylation only
through the involvement of HER3. As seen in Fig. 5 A,
,10% of the total cellular EGFR gets phosphorylated when
stimulated with NRG (dashed lines). This suggests a low
EGFR-HER3 heterodimerization propensity in the presence
of the HER3 ligand. Increase in the HER3 expression only
slightly increases the EGFR phosphorylation. In contrast,
when EGF is used as the ligand, ;70% of EGFR gets phos-
phorylated via homodimerization in the absence of HER3.
Upon increasing HER3 expression in these EGF-stimulated
cells, EGFR-HER3 heterodimers begin to out-compete some
of the EGFR homodimers. EGFR-HER3 heterodimers in this
scenario can only have single ligand occupancy, due to the
lack of the HER3 ligand in these simulations. Hence, these
heterodimers are not as effective at yielding EGFR phos-
phorylation as EGFR homodimers would be. The net result
is a reduction in EGFR phosphorylation when HER3 ex-
pression is increased. Overall, HER3 expression does not
contribute signiﬁcantly to EGFR phosphorylation in this
system.
Next we examined the case where cells were made to
express 200,000 each of EGFR and HER3, while the level of
HER2 was varied (Fig. 5 B). These simulations were per-
formed to explore whether HER2 enhances EGFR-HER3
communication via lateral information transfer. As seen,
when neuregulin alone is used as the ligand, ;7% of EGFR
gets phosphorylated even in the absence of HER2. Increas-
ing HER2 expression to 200,000 receptors enhances EGFR
phosphorylation to ;10%. This suggests the existence of
FIGURE 4 Effects of HER2 and HER3 on EGFR internalization and
degradation. Simulations were performed where EGFR was expressed
at 200,000 molecules either alone or in conjunction with HER2 and
HER3. Results are presented in both panels for ﬁve simulated cases, and
the curves are numbered in the following order: 1, EGFR alone 1 EGF; 2,
EGFR1HER31EGF; 3, EGFR1HER31EGF1NRG; 4, EGFR1HER21EGF;
and 5, EGFR1HER21HER31EGF1NRG. (A) EGFR internalization quan-
tiﬁed using the inside/surface ratio of receptors. (B) EGFR degradation seen
as a drop in the total number of receptors with time after addition of ligand
stimulus. Arrows in the plots indicate the directions along which the curve
labels increase.
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modest levels of lateral information transfer. In this scenario,
the effect of HER2 on EGFR in the absence of HER3 is
expected to be modest since there is no EGF in the system.
The presence of HER3 and its ligand would result in HER2
phosphorylation through the formation of HER2-HER3
heterodimers. In the model, these heterodimers can dissoci-
ate yielding phosphorylated HER2 monomers, albeit at a low
rate. If these activated HER2 monomers complex with an
EGFR before getting dephosphorylated, the EGFR in the
resultant dimer can get efﬁciently trans-phosphorylated.
When the stimulating ligand is EGF (Fig. 5 B, solid lines),
HER2 again has only a modest effect on EGFR phosphor-
ylation. Overall, our model exhibits elements of HER2-
mediated lateral information transfer, which can be
interpreted as arising due to the dynamic formation and
breakup of receptor dimers. Speciﬁcally, the lateral trans-
formation transfer occurs due to the initial phosphoryla-
tion of HER2 in HER2-HER3 heterodimers. These dimers
then dissociate, yielding phosphorylated HER2 monomers,
which then engage with and phosphorylate EGFR mole-
cules.
It would be of interest to examine the extent of lateral
information transfer using experiments mimicking these
simulation conditions. By knocking down the expression of
HER2 and by using antibodies to block HER2 from forming
heterodimers with other receptors, it would be possible to
investigate the role of HER2 as the mediator of interaction
between EGFR and HER3 receptors. It is reasonable to sug-
gest that real cells could display increased HER2-mediated
transfer beyond what is predicted by our model. It has been
suggested that HER family receptors are capable of forming
higher order oligomer complexes (8,52). That being the case,
the diffusion-mediated collision of a free EGFR with a
HER2-HER3 heterodimer could activate EGFR in such a
trimeric complex. This is one possible means of obtaining in-
creased lateral transfer other than that predicted by our
model, which is restricted to dimer species.
Parametric sensitivity of system outputs and
experimental observables
Dimerization afﬁnities play a major role in controlling the
dimer distribution within the cell
In our mathematical model, the formation of dimers of a
given type is dictated by a complex interplay among the
reversible reactions of ligand binding, dimerization, phos-
phorylation, and trafﬁcking. We sought to identify the key
reactions among these that serve as controlling entities in
determining the model output by performing parametric
sensitivity analysis. Simulations were performed for cells
coexpressing 200,000 receptors each of EGFR, HER2, and
HER3. Each of the 54 parameters in our model was increased
by 10%, one at a time, and the effect of these changes on the
dimer distribution was analyzed. Table 2 lists the parameter
changes that result in a .2% change in the number of
activated dimer species. Results are presented for both the
total number of dimers in the cell and the number of dimers
at the plasma membrane. As seen from Column 1 of Table 2,
the EGFR-EGF binding and dissociation rates (parameters
1 and 6) affect the number of homo- and heterodimers
involving EGFR. Similarly, the HER3-NRG afﬁnity (pa-
rameters 2 and 7) has a bearing on the number of EGFR-
HER3 heterodimers. When receptor dimerization afﬁnities
(Column 2) are examined, the competitive nature of the
dimerization process becomes apparent. For instance, an in-
crease in the dissociation rate of EGFR homodimers (pa-
rameter 13) not only has the direct effect of reducing the
number of EGFR homodimers but also results in an increase
in the number of EGFR-HER2 and EGFR-HER3 dimers.
FIGURE 5 The EGFR-HER3 interaction. The extent of EGFR phospho-
rylation in response to EGF and NRG are plotted for cases when EGFR is
coexpressed with (A) HER3 alone in the absence of HER2 and (B) varying
amounts of HER2 in the presence of a constant amount of HER3. Varying
the levels of HER2 and HER3 has a minimal effect on the extent of EGFR
phosphorylation. Whereas increasing HER2 causes a slight increase in
EGFR phosphorylation, increasing HER3 slightly decreases EGFR phos-
phorylation in response to EGF. The NRG response is evidence of cross-
activation of EGFR either by ligand-bound HER3 (A) or by HER2 activated
by ligand-bound HER3 (panel B).
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The relationship between receptor phosphorylation and
dephosphorylation rates (Column 3) on the number of active
dimers is relatively simpler. Increasing the rate of receptor
phosphorylation for a given dimer increases the number
of activated molecules of that dimer, and increasing the
corresponding dephosphorylation rate has the opposite
effect. Analysis of the effect of trafﬁcking rates on dimer
distribution (Column 4) yields intuitively apparent results.
The number of molecules of a given dimer species increases
when receptor recycling rates (parameters 43 and 47) are
increased. Increasing the coated-pit vesicle formation rate
(parameter 41) and the fraction of receptors incorporated into
these vesicles (parameters 49–52) results in a decrease in
the number of dimer species at the plasma membrane. It is
interesting to note that the number of HER2-HER3 hetero-
dimers (Row 4) does not display a marked dependence either
on the HER2-HER3 afﬁnity or on the dimerization afﬁnities
of the competing species (Row 4; Columns 1 and 2). This
follows from the increased NRG binding afﬁnity of these
dimers. The 10-fold-lower dissociation rate of NRG from the
HER2-HER3 heterodimer thus makes the number of HER2-
HER3 dimers a robust quantity.
For the model to be able to reliably predict the dimeriza-
tion pattern in a given cell type it is critical to quantify the
parameters listed in Table 2 to a greater degree of accuracy
than what would be acceptable for the other model param-
eters. Of these critical parameters, the dimerization afﬁnities
are unique in that altering a single afﬁnity has wide-ranging
consequences on the overall dimer distribution within the
cell. These afﬁnities can be estimated using techniques such
as ﬂuorescence resonance energy-transfer imaging of labeled
dimers (32,53–55) or through protein coimmunoprecipita-
tion experiments (18). However, accurate quantiﬁcation of
dimerization afﬁnities from these experimental results is still
a nontrivial task. In the following section we describe how
the kinetic model can be used to address the problem of
parameter estimation by enabling the design of relatively
facile experiments from which parameters such as the dimer-
ization afﬁnities can be extracted.
Using the model to deﬁne measurement strategies for
dimerization afﬁnities
Before a model can be used in a predictive fashion for a
speciﬁc cell type it is necessary to establish the validity of the
parameter values in the chosen experimental system. Al-
though some parameters, such as receptor-ligand afﬁnities,
may be independent of cell type, other parameters may be
dependent upon the cell type and on the experimental con-
ditions used for the measurement. A way of effectively
addressing this issue is to perform experiments in the chosen
cell type and to use this experimental data in conjunction
with the mathematical model to estimate model parameters.
A corollary conjuncture to this would be to use the model
itself to choose the types of experimental measurements that
need to be made to estimate a speciﬁc set of parameters.
As an illustration of this approach we sought to identify
experimental measurements that could be used to estimate
the dimerization afﬁnities in our kinetic model. As described
in Methods, we considered a set of nine possible experimen-
tal measurements and four possible cell lines. The experi-
mental observables considered were the total receptor mass
of EGFR, HER2 and HER3, the fractional phosphorylation
of the three receptors and the In/Sur ratio of the phosphor-
ylated forms of the three receptors. The cell lines chosen
expressed various combinations of EGFR, HER2, and HER3
receptors. Each of the dimerization parameters (parameters
13–20) was varied and the RMSD was used to identify the
measurement that would be most sensitive to the variation of
each of the parameters (see Methods). Fig. 6 presents the
RMSD values for various choices of experiments for two of
the dimerization parameters—the basal rate for dissociation
of EGFR homodimers (parameter 13) and the enhancement
in dimer dissociation rate when a receptor is dephosphory-
lated (parameter 19). The HER3 phosphorylation ratio in a
cell line coexpressing EGFR and HER3 is the observation
that displays the highest sensitivity to parameter 13 (Fig.
6 A). Therefore, if the aim is to better deﬁne the value of
parameter 13 (the EGFR homodimer dissociation rate),
TABLE 2 Critical parameters determining model output
Ligand binding Receptor dimerization Receptor phosphorylation Trafﬁcking
Output variable 1  1  1  1 
EGFR-EGFR Total 1 6 15,18 13,17 23,29 47
Surface 15,18 13,17 23,29 43,47 41,45,49–52
EGFR-HER2 Total 6 13,17 25,28,29 35,39,40
Surface 12,17 15 25,28,29 35 43,47 41,49–51
EGFR-HER3 Total 2 6,7,11 13 18 27,28,29 38 47 41,49
Surface 7,11 13 18 27,28,29 43,47 41,49–52
HER2-HER3 Total 17 26,28,29 37
Surface 26,28,29 37 47 41,49
Parametric sensitivity analysis was performed by increasing each of the 54 model parameters (listed in Table 1) by 10%, one at a time, and studying the effect
of this increase on the levels of activated dimers both at the whole-cell level and at the plasma membrane. Parameters that elicit a .2% change in the
concentrations of the speciﬁc dimer species are listed. Parameter changes that result in an increase in the output, are listed in the plus (1) column; parameters
whose increase results in a decrease in the output, are listed in the minus () column.
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measurement of HER2 phosphorylation ratio would be the
most informative experiment to perform. Similarly Fig. 6 B
shows that a good experiment to estimate parameter 19
would be the measurement of the inside/surface ratio of
HER2 in a cell line coexpressing EGFR and HER2. The
results also indicate that measurements of EGFR In/Sur ratio
and the HER2 phosphorylation fraction in the same cell line
could provide adequate data sets for estimation of parameter
19. In such a scenario the actual choice of experiments can be
guided by the availability of antibodies and other such
operational concerns regarding the experiment.
Table 3 lists the measurement variable and the cell line
that would provide the best data set for the estimation of the
various dimerization parameters in the model. Two exper-
iments stand out in their ability to simultaneously provide
information about a number of parameters. The ﬁrst such
measurement is that of the HER3 phosphorylation ratio in a
cell line coexpressing EGFR and HER3. It is known that
HER3 is kinase-deﬁcient and can only be phosphorylated
when it forms heterodimers with EGFR in this cell line.
Hence, it should not be surprising that this measurement is
effective in providing information about homo- and hetero-
dimerization rates for EGFR and HER3. The second mea-
surement providing the best data set for the estimation of
multiple parameters is the measurement of HER2 In/Sur ratio
in a cell line coexpressing EGFR and HER2. The internal-
ization of HER2 is contingent upon its dimerization with
ligand-bound EGFR. Hence, the extent of HER2 internali-
zation serves as a good readout for HER2 homo- and hetero-
dimerization afﬁnities. It is clear from these results that the
choice of the appropriate measurement for a given model
parameter is not always intuitively obvious due to the com-
plexity of the system. We believe that our approach to choose
the most appropriate experimental measurement for estimation
of model parameters may prove to be valuable in system-
atically constructing well-parameterized predictive models
and in designing new sets of experiments.
Phenotypic consequences of HER2 and
HER3 overexpression
As mentioned earlier, the objective of this work is to provide
computational tools for the establishment of a mechanistic
link between HER overexpression and cellular transfor-
mation. Although it is possible to develop a detailed kinetic
model for HER dimerization and activation, the complex
nature of downstream signal transduction and its effects
on cell phenotype impede the development of kinetic models
for these stages of the process. However, it is possible to
construct intuitive mathematical expressions describing the
link between receptor activation and cell phenotype, which
may facilitate the interpretation of experimental data. Equa-
tion 2 for the cell phenotype is one such expression. Ex-
plicitly stated, this equation suggests that the change in
phenotype elicited in a cell stimulated by EGF and NRG
depends upon the number of heterodimers of each type
formed in the cell and on the potencies of each of these
heterodimers. Introduction of this equation enables us to
place the mechanisms behind transformation on a quantita-
tive footing wherein the details of the process are captured by
the b- and g-parameters, the potencies of EGFR-HER3 and
HER2-HER3 heterodimers relative to that of the EGFR
homodimers, respectively. Using this equation, we examined
the potential consequences of the receptor dimerization hier-
archy on cell phenotype (Fig. 7). Speciﬁcally we attempted
to address the question of whether coexpression of EGFR
FIGURE 6 Experimental design for parameter estimation. The model was
run and the values of experimental observables were generated as a function
of time using the base parameter set (base curves) and a parameter set with a
10% increase in a single model parameter (modiﬁed curves). The difference
between the base curve and the modiﬁed curve was quantiﬁed using the
relative root-mean-squared difference (RMSD) between the two curves (see
the text). The experimental observables considered are the total receptor
mass, the phosphorylation ratio, and the inside/surface ratio (denoted I/S
in the ﬁgure) for the three receptors. The relative RMSD is plotted for
these experimental outputs measured in four different cell lines for (A) a
10% change in parameter 13, the basal rate for the dissociation of
EGFR homodimers; and (B) a 10% change in parameter 19, which is the
enhancement in dimer dissociation rate when a receptor in a dimer becomes
unphosphorylated. As seen, the fractional HER3 phosphorylation in a cell
line expressing EGFR and HER3 would be the best output if one is
interested in estimating parameter 13. Similarly, measurement of the HER2
In/Sur ratio in an EGFR-HER2 cell line provides the best estimate for
parameter 19.
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with both HER2 and HER3 at low-to-moderate levels would
enable a cell to match the phenotype of a cell expressing
EGFR along with extremely high levels of HER2 (600,000
receptors).
For the computations in Fig. 7, all cells were assumed
to express 200,000 EGFR molecules while the expression
levels of HER2 and HER3 were varied. The kinetic model
was solved to obtain the number of dually phosphorylated
dimers of various types required by Eq. 2 for the compu-
tation of the phenotype. For the results presented here, re-
ceptor activation levels 1 h after ligand stimulation were used
to determine the phenotype. Employing the time-integral of
receptor activation to determine the phenotype yielded qual-
itatively similar results (results not shown). In Fig. 7 A we
present results for the scenario where HER2-HER3 hetero-
dimers are only as potent as EGFR homodimers, i.e., g is set
to equal 1, and the critical levels of HER2 and HER3 re-
quired to match the phenotype value P* of the reference cell
line (expressing 600,000 HER2 molecules) were determined.
As seen, for the case where EGFR-HER3 dimers do not
make any phenotypic contribution (b ¼ 0), cells expressing
200,000 EGFR and 200,000 HER3 molecules need
;200,000 HER2 molecules to display the phenotype P*.
Setting b ¼ 1 reduces the HER2 requirement to ,100,000
molecules. In other words, cells expressing a combined HER2
and HER3 receptor number of,300,000 are capable of mim-
icking the phenotype of a cell line expressing 600,000 HER2
receptors. As noted earlier, the HER2-HER3 heterodimer is
believed to be the most potent signaling entity in the HER-
receptor family. Thus, in reality, g-values are expected to be
1. In Fig. 7 B, we examine the critical potency gcrit
required to match the reference phenotype P* in cells ex-
pressing various combinations of HER2 and HER3 receptor
numbers. For these computations, the EGFR-HER3 hetero-
dimer was assumed to have no potency (b ¼ 0). As seen,
cells expressing a mere 50,000 each of HER2 and HER3
receptors are enabled to match the phenotype of a 600,000
HER2 expresser if the HER2-HER3 heterodimer is approx-
imately nine times more potent than the EGFR homodimer.
In addition, the ﬁgure nicely illustrates the nonlinear response
characteristics of the model system.
Overall, our results indicate that HER3 can have a pro-
found impact on cell phenotype through the enhanced re-
cruitment of HER2 receptors into a potent signaling moiety.
We are currently setting up experiments in cell lines ex-
pressing varying amounts of EGFR, HER2, and HER3 to test
these predictions. In addition, the experiments will enable us
to reﬁne Eq. 2 into a more comprehensive deﬁnition of the
physico-chemical factors that govern cellular responses me-
diated by the HER family of receptors.
SUMMARY AND CONCLUSIONS
The utility of mathematical modeling as a tool to understand
cell biology is increasingly being recognized. Models can
serve the dual role of providing 1), predictive capability
obviating the need for repeated experiments; and 2),
mechanistic information about how a cell converts environ-
mental cues to an eventual phenotypic outcome. Further-
more, mathematical models can be used as powerful tools
to organize knowledge in the era of systems biology. The
necessity for quantitative precision in the deﬁnition of a
model motivates one to critically examine relevant experi-
mental data, formalize the assumptions regarding mecha-
nisms, and enables one to uncover gaps in knowledge. Extant
information on molecular interactions, concentrations, and
reaction rates within the cell serve to restrict the scope and
the detail of models in cell biology. Toward one end of the
spectrum processes such as receptor-ligand binding, receptor
phosphorylation and vesicle trafﬁcking are sufﬁciently well
quantiﬁed to warrant the use of detailed kinetic representa-
tions. Toward the other end, information about processes
such as transcription and translation and the manner in which
a second messenger concentration dictates a biological out-
come is currently not amenable to kinetic modeling. Hence,
the development of predictive models that can establish a
TABLE 3 Experiments to be performed for estimation of dimerization parameters
Parameter No. Parameter description Output to be measured Cell line
13 BR for EGFR homodimer dissociation. HER3 phosphorylation EGFR/HER3
14 BR for HER2 homodimer dissociation. HER2 In/Sur ratio EGFR/HER2
15 BR for EGFR-HER2 dissociation. EGFR In/Sur ratio EGFR/HER2
16 BR for HER3 homodimer dissociation. HER3 phosphorylation EGFR/HER3
17 BR for HER2-HER3 dissociation. HER3 phosphorylation EGFR/HER2/HER3
18 BR for EGFR-HER3 dissociation. HER3 phosphorylation EGFR/HER3
19 Dissociation rate enhancement upon dephosphorylation. HER2 In/Sur ratio EGFR/HER2
20 Dissociation rate enhancement upon ligand removal. HER3 phosphorylation EGFR/HER3
50 Enhanced incorporation factor for ligand-bound EGFR. EGFR In/Sur ratio EGFR
51 Enhanced incorporation factor for ligand-bound EGFR-HER2. HER2 In/Sur ratio EGFR/HER2
52 Enhanced incorporation factor for ligand-bound EGFR-HER3. HER3 In/Sur ratio EGFR/HER3
BR stands for the basal rate. The relative RMSD between experimental observables generated using the base parameter set and a parameter set with a 10%
change in a single model parameter was computed for all the dimerization parameters for four possible HER-expressing cell lines. These RMSD values were
used to determine the experimental output that would serve to provide the best data set for estimation of each of the parameters listed. Experiments that turn
out to be the best ones for the estimation of multiple parameters are italicized.
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link between a stimulus and a biological response requires
the integration of mathematical descriptions of cellular pro-
cesses, which may vary vastly in their degree of detail. We
describe the development of a predictive model that strives to
establish a link between receptor expression levels and cell
phenotype for the human epidermal growth factor receptor
(HER) system.
We have demonstrated how detailed kinetic models of
receptor dimerization and trafﬁcking that are permissible by
virtue of the quantitative information available can be com-
bined with crude curve-ﬁtting type approaches to establish a
link between HER overexpression and cellular transforma-
tion. The major results of our analysis and their implications
are highlighted below:
1. Our kinetic model brings together the available quanti-
tative information about receptor-ligand binding, dimer-
ization, phosphorylation, and trafﬁcking properties of the
EGFR family of receptors, and presents it in the form of a
concise mathematical model. Using the model, we dem-
onstrated how the current literature on rate constants for
receptor-ligand binding and dimerization lead naturally
to the enhanced formation of HER2-HER3 heterodimers
in cells coexpressing HER1-3 receptors. It has been
previously shown that coexpression of HER2 and HER3
has a synergistic effect on cell transformation (56,57).
Our results indicate that this effect can be explained in part
due to the enhanced formation of HER2-HER3 dimers.
2. We found that coexpression of EGFR with HER2 and
HER3 retards EGFR internalization and degradation,
thereby prolonging signaling through the EGFR while
decreasing the bias toward endosomal compartments.
This could be an additional reason for the synergistic
effect of receptor coexpression on cell transformation.
3. We have utilized the developed model to design exper-
iments aimed at estimating the dimerization afﬁnities of
different receptor types. Parameter sensitivity analysis
revealed that measurements of HER3 phosphorylation in
cells coexpressing EGFR and HER3 and the HER2 inter-
nalization ratio in cells coexpressing EGFR and HER2
would be especially useful for the estimation of critical
model parameters. We plan to incorporate these ﬁndings
into the design of our planned experiments to validate
and to better parameterize our model.
4. The reaction network presented here can be easily
adapted to develop models for other receptor signaling
systems where receptor dimerization and trafﬁcking play
a similarly important role.
5. We have used a simple intuitive expression grounded in
our qualitative understanding of the biological system to
explore the possible effects of our model predictions on
biological response. This analysis indicates that coex-
pression of HER1–3 at low-to-moderate levels may
enable a cell to match the phenotype of a cell expressing
very high levels of EGFR and HER2. This result is both
due to the enhanced formation of HER2-HER3 hetero-
dimers and to the enhanced potency of this dimer species
when it comes to transformation. Such approaches
borrowed from engineering and statistical sciences could
prove to be valuable in designing experiments aimed at
dissecting the mechanistic link between molecular level
events and biological endpoints.
APPENDIX A: EQUATIONS GOVERNING THE
KINETIC MODEL
The concentration of a species in a speciﬁc type of compartment can change
due to one of two reasons. The species can be 1), generated and destroyed
through a biochemical reaction; or 2), transported in and out of the com-
partment due to vesicle trafﬁcking. The ﬂux for species i in compartment C
FIGURE 7 Effect of receptor expression levels on phenotype. Computa-
tions were performed for cells coexpressing 200,000 EGFR molecules and
varying levels of HER2 and HER3 molecules. In both plots the receptor
expression levels have units of thousands of molecules. (A) Critical HER2
required to match the phenotype P* of the reference cell line as a function of
HER3 expression at three different b-values (EGFR-HER3 potencies). For
all cases, HER2-HER3 potency is set at g ¼ 1. (B) Critical HER2-HER3
potency g required to match P* for cell lines expressing varying levels of
HER2 and HER3. For all cases, EGFR-HER3 potency is set at b ¼ 0.
Results indicate that coexpression of all three receptor subtypes at low-to-
moderate levels may enable a cell to match the phenotype of a high HER2
expresser.
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can be written as the linear combination of the ﬂux contributions due to these
processes as
F
i
C ¼ dxiC=dt ¼ uiC1 viC; (A1)
where FiC is the net ﬂux for species i in compartment C, x
i
C is the
concentration of species i in compartment C, and uiC and v
i
C are the net
biochemical reaction and trafﬁcking ﬂuxes for species i in compartment C.
For a given set of rate constants, ﬂux uiC can be computed based on the
reactions that species i participate in. The trafﬁcking ﬂux for species i in the
various compartments depends upon the abundance of various types of
vesicles in the cell. These vesicle concentrations in turn evolve according to
the equations
dNCP=dt ¼ kPM-CP  kCP-LE NCP  kCP-PM NCP; (A2a)
dNSP=dt ¼ kPM-SP  kSP-LE NSP  kSP-PM NCP1 kLE-SP NLE;
(A2b)
dNLE=dt ¼ kCP-LE NCP1 kSP-LE NSP  kLE-LY NLE  kLE-SP NLE;
(A2c)
where NCP, NSP, and NLE are the number of coated-pit (CP), smooth pit (SP),
and late endosomic (LE) vesicles, respectively. These variables have units
of unit-vesicle size. In Eq. A2, kxx-yy are the rate constants encoded such that
xx is the two-letter code for the source compartment, whereas yy is that for
the target compartment. Thus kPM-CP is the zero-order rate constant for
the formation of coated-pit vesicles from the plasma membrane, while kLE-LY
is the ﬁrst-order rate constant for the merging of a vesicle from the late
endosome into the lysosome.
The trafﬁcking ﬂux for species i in the various compartments can be
written in terms of the vesicle abundances and the rate constants for vesicle
trafﬁcking as
v
i
PM ¼ aixiPM kPM-CP  bixiPM kPM-SP1 xiCP kCP-PM NCP
1 xiSP kSP-PM NSP; (A3a)
v
i
CP ¼ðaixiPM kPM-CP  xiCP kCP-PM NCP  xiCP kCP-LE NCP
 xiCP dNCP=dtÞ=NCP; (A3b)
viSP ¼ðbixiPM kPMSP  xiSP kSPPM NSP  xiSP kSP-LE NSP
1 diðxiLE=NLEÞkLE-LYNLE  xiSP dNSP=dtÞ=NSP; (A3c)
v
i
LE ¼ xiCP kCP-LE NCP1 xiSP kSP-LE NSP  giðxiLE=NLEÞ
3 kLE-SP NLE  diðxiLE=NLEÞkLE-LY NLE; (A3d)
v
i
LY ¼ diðxiLE=NLEÞkLE-LY NLE; (A3e)
where vizz is the trafﬁcking ﬂux for species i in compartment zz in units of
molecules per unit time. The values ai and bi are incorporation coefﬁcients
for species i into coated-pit and smooth-pit vesicles forming from the PM,
respectively. The values gi and di are multiplication factors that account for
the increased propensity of a species to get recycled from the LE or targeted
from the LE to the lysosome, respectively. The value xiPM is the total number
of molecules in the plasma membrane, and xiCP and x
i
SP are the number of
molecules in a single coated-pit vesicle and a single smooth-pit vesicle,
respectively. The total number of molecules of species Xi in the EE is thus
xiCPNCP1x
i
SPNSP: Similarly, xLE
i is the total number of molecules in the LE
compartment. The differential trafﬁcking properties of the various receptor
monomers and dimers of the HER family are captured in our model by
specifying different incorporation coefﬁcients (ai and bi) for the various
receptor species. A species that tends to internalize more rapidly is given a
higher early endosome incorporation coefﬁcient, while a species that gets
degraded more rapidly would have a higher value of di.
Solution of the model entails simultaneous solution of the system of
ordinary differential equations obtained by combining Eqs. A1–A3. For a
given receptor expression level, the receptors are initially assigned to the
plasma membrane in the form of ligand-free, unphosphorylated monomers.
Thus, at time t ¼ 0, the concentrations of all species except R1FU, R2FU,
and R3FU are set to equal zero. In addition, the simulation is started with a
coated-pit, smooth-pit and sorting endosome number of one each. Equations
A1 and A3 are then solved in the absence of ligand until t¼ 5 h to generate a
steady-state distribution of vesicles and receptors in the cell, and this
conﬁguration is used as the initial starting point for later simulations in-
vestigating the response to ligand stimuli. Subsequently ligand is added to
the system and the time-evolution of species concentrations is computed by
solving the system of differential equations. The raw-species concentration
proﬁles resulting from solution of the mathematical model were analyzed to
extract relevant information such as the fraction of phosphorylated receptors,
the In/Sur ratio of the receptors, and the dimerization fractions for the vari-
ous receptors.
APPENDIX B: RATE CONSTANTS FOR THE
KINETIC MODEL
The combinatorial nature of the dimerization model necessitates the
speciﬁcation of rate constants for 308 biochemical reactions for each of the
cellular compartments.We tackle this problem by specifying reaction rates in
terms of a representative or basal rate for a speciﬁc species that serves as a
reference complex for an entire class of reactions. In addition, we specify how
the rate constants would change if the phosphorylation or ligand-binding state
of this reference species were to change. A rate constant value for a reaction
involving any given species is obtained as the product of the basal rate for the
class to which the reaction belongs and the multiplier for the species. We
consider each of the reaction types one by one and describe how actual rate
constants are derived from the parameter list presented inTable 1. For the sake
of brevity, the parameter number n from Table 1 is written as pn.
Receptor-ligand binding and dissociation
The parameters for the binding of EGF to EGFR andNRG to HER3 are based
on Jones et al. (39) and French et al. (58). The basal rates for ligand binding
and dissociation represent the rate constants for reactions at the plasma
membrane (p1, p2, p6, p7). These rates are assumed to be independent of
receptor dimerization and phosphorylation state. However, they are adjusted
to correct for the effect of pH in intracellular compartments. Speciﬁcally the
association and dissociation rates are multiplied by 0.135 (p3) and 4.125 (p8),
respectively, to obtain the corresponding intracellular rates for EGF-EGFR
complexes (58). NRG–HER3 complexes are assumed to display a pH-
dependent enhancement in ligand dissociation similar to that of TGFa-EGFR
complexes, i.e., the plasma membrane association rate is multiplied by 0.l35
(p4) and the dissociation rate is multiplied by a value of 8.25 (p9) to obtain the
endosomal rates for these complexes (42). This assumption has the effect of
inducing enhanced recycling of HER3 receptors, similar to that observed for
TGFa-EGFR complexes. The dissociation of neuregulin from HER2-HER3
heterodimers is assumed to be 10-times slower than the basal rate indicated
(p10) (18,39). Further, In EGFR-HER3 heterodimers the presence of NRG
halves the EGF on-rate (p5) and increases the EGF off- rate by a factor of
1.5 (p11) (40).
Receptor dimerization and dimer dissociation
The dimerization rates have been adapted from Resat et al. (42) and
Kholodenko et al. (46). Dimerization is assumed to be diffusion-limited. A
constant value is used for all receptor types. Dimer dissociation is assumed
to occur at the basal rate when both receptors are ligand-bound and
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phosphorylated. Thus, p13 represents the rate constant for the reaction
R1BPR1BP/R1BP 1 R1BP. Dephosphorylation of each receptor is as-
sumed to double the rate of dimer dissociation. Removal of each ligand is
assumed to further induce a ﬁvefold increase in the dissociation rate. For
example, the reaction R1BPR1FU/R1BP 1 R1BP would have a rate
constant equal to 10-times (2 3 5) the value speciﬁed for p13. This is
because this dimer is obtained after dephosphorylation and ligand dissoci-
ation from one of the receptors in the reference species R1BPR1BP. In
dimers involving HER2, HER2 is assumed to behave as if it were ligand-
bound, for the purpose of determining the dimer dissociation rate. This is in
agreement with models based on crystallographic data (59,60), which indi-
cate that HER2 may constitutively present a conformation that is conducive
to receptor dimerization (41). In dimers involving HER3, the receptor is
assumed to behave similar to EGFR in terms of its dissociation properties.
Receptor phosphorylation and dephosphorylation
The receptor phosphorylation and dephosphorylation rates have also been
adapted from Resat et al. (42) and Kholodenko et al. (46). The phosphoryl-
ation rates of free (no-ligand) EGFR, HER2, and HER3 receptor monomers
are set to 0. Phosphorylation of EGFR homodimers is assumed to occur at the
basal rate when both receptors are free and unphosphorylated. Thus, p23
represents the rate constant for the reaction R1FUR1FU/R1FUR1FP.
Each ligand bound to the complex is assumed to double the phosphorylation
rate (p29). If one of the receptors is already phosphorylated, phosphorylation
is assumed to proceed at three times the basal rate (p28). EGFR-HER3,
HER2-HER3, and EGFR-HER2 dimers are assumed to have 80%of the basal
phosphorylation rate of the corresponding EGFR homodimers. Dephospho-
rylation of EGFR homodimers is assumed to occur at the basal rate when both
receptors are ligand-bound and phosphorylated. Thus, p33 represents the rate
constant for the reaction R1BPR1BP/ R1BUR1BP. Whereas removal of
each ligand causes a fourfold increase (p40) in the dephosphorylation rate, the
presence of one unphosphorylated receptor further doubles the rate (p39).
HER2 is assumed to behave as if it were a ligand-bound receptor, for the
purpose of determining phosphorylation and dephosphorylation rates.
Vesicle trafﬁcking rates
Parameters 41–48 were taken from Resat et al. (42). These parameters were
determined by making the following assumptions:
1. The half-life of early endosomal vesicles is 5 min.
2. Ninety-percent of smooth pit endosomes recycle to the plasma
membrane (the rest merge into sorting endosomes).
3. Thirty-percent of coated-pit vesicles recycle to the plasma membrane.
4. The lifetime of a sorting endosome is 45 min.
5. Five-percent of sorting endosomes get degraded.
These parameters specify the rates kxx-yy in Eqs. A2 and A3 of Appendix A.
Receptor incorporation factors
Parameter 49 represents the value for the incorporation coefﬁcients (denoted
as ai and bi in Eq. A3 in Appendix A) for the case of receptor species, which
have no bound ligand. The incorporation coefﬁcient b of ligand-bound
EGFR in coated-pit endosomes is 15.5 times (p50) higher than this value.
Similarly, the b-values of ligand-bound EGFR-HER2 and EGFR-HER3
heterodimers is 5.4 times higher than the basal incorporation coefﬁcient.
These multiplier values are given by p51 and p52, respectively.
Receptor recycling and degradation factors
All gi values are set to equal 1 in the model, i.e., all of the receptors are
assigned the same propensity for getting incorporated into a vesicle re-
cycling from the LE to the plasma membrane. The degradation of molecules
in the late endosome occurs at a basal rate dictated by a uniform concentration-
dependent incorporation into pseudo-vesicles targeted for lysosomal deg-
radation. The presence of one EGF molecule on a receptor complex causes a
threefold increase (p53) in its incorporation rate, whereas the presence of
two EGF molecules causes a sixfold increase (p54) in the rate. These
parameters provide values for the variable di in Eq. A3 of Appendix A.
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